Europe Frontotemporal Dementia Market By Drug Class Type (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others), By Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others), By Country, Competition, Forecast & Opportunities, 2028

Europe frontotemporal dementia market is expected to witness significant growth during the forecast period, 2024-2028. Growing prevalence of dementia along with growing aging population in the region is anticipated to facilitate the growth of the market. The gradual increase in the number of new cases of dementia registered directly every year are strengthening the growth of the frontotemporal dementia market. Moreover, the rising fundings provided by government as well as by the several non-profit organizations for the target disease care, support, and R&D activities to develop new drug are the major factor propelling the growth of the market. Furthermore, the advent of novel Frontotemporal dementia therapies as well as new diagnosing biomarkers are projected to augment the growth of the market. Rising number of clinical trials in the region are propelling the growth of the market.

Frontotemporal dementia refers to a group of uncommon brain disorders that primarily affect the frontal and temporal lobes of the brain. These areas of the brain are generally associated with personality, behavior and language. It often begins between the age of 40 and 65.

Growing Prevalence of Dementia

In 2019, the occurrence of dementia in Europe was roughly 188 per 100,000 population.

Increasing Number of Clinical Trials

Recent Developments

• In 2022, AviadoBio, a pioneering,pre-clinical stage, gene therapy company emphasized on developing anddelivering transformative medicines for patients with neurodegenerativedisorders, announced that both the U.S. Food and Drug Administration (FDA) andthe European Commission (EC) have granted orphan designation to AVB-101, aone-time gene therapy for the treatment of frontotemporal dementia (FTD).
• In 2021, Centogene N.V., acommercial-stage company emphasized on producing data-driven insights todiagnose, understand, and treat rare diseases, announced that they haveenrolled first patient in the international EFRONT Study, an observationalstudy to know the prevalence of genetic mutations in patients withfrontotemporal dementia (FTD).

Market Segmentation

Europe frontotemporal dementia market is segmented into

Market Players

GlaxoSmithKline PLC, Eli Lilly Italia S.p.A., Pfizer Deutschland GmbH., F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca GmbH, Sanofi S.A, Allergen plc, Johnson & Johnson and Viatris Inc are some of the leading companies operating in the Europe Frontotemporal Dementia market.